Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Foghorn Therapeutics Inc (NQ: FHTX )

5.830 -0.160 (-2.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 239,006
Open 6.030
Bid (Size) 4.500 (1)
Ask (Size) 8.650 (1)
Prev. Close 5.990
Today's Range 5.670 - 6.130
52wk Range 4.510 - 9.970
Shares Outstanding 36,936,886
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML
From Foghorn Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-10.31%
-10.31%
1 Month
-24.77%
-24.77%
3 Month
-28.82%
-28.82%
6 Month
-3.00%
-3.00%
1 Year
-30.43%
-30.43%

More News

Read More
Foghorn Therapeutics Announces Chief Medical Officer Succession
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
What 5 Analyst Ratings Have To Say About Foghorn Therapeutics
Via Benzinga
Analyst Ratings for Foghorn Therapeutics
Via Benzinga
What 6 Analyst Ratings Have To Say About Foghorn Therapeutics
Via Benzinga
Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Schrödinger To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
Via Benzinga
Analyst Expectations for Foghorn Therapeutics's Future
Via Benzinga
Expert Ratings for Foghorn Therapeutics
Via Benzinga
Foghorn Therapeutics Shifts Focus from Development Of Cancer Hopeful with Eye Cancer
Via Benzinga
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Crude Oil Up 1.5%; Philips Shares Jump After Q1 Results
Via Benzinga
Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
US Stocks Turn Lower; Nasdaq Dips 100 Points
Via Benzinga
More Trouble For Foghorn Therapeutics: After Blood Cancer Trial, FDA Puts Another Cancer Trial On Clinical Hold
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Foghorn Therapeutics Provides an Update on FHD-609
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.